G. Weerakkody

发表

ADCY9 Genetic Variants and Cardiovascular Outcomes With Evacetrapib in Patients With High-Risk Vascular Disease: A Nested Case-Control Study

A. Lincoff, S. Nissen, E. McErlean, 2018, JAMA cardiology.

Clopidogrel poor responders: An objective definition based on Bayesian classification

K. Winters, G. Weerakkody, J. Jakubowski, 2007, Platelets.

Mortality benefit with prasugrel in the TRITON-TIMI 38 coronary artery bypass grafting cohort: risk-adjusted retrospective data analysis.

Peter K. Smith, R. Poston, L. Goodnough, 2012, Journal of the American College of Cardiology.

Population Pharmacokinetic Analyses to Evaluate the Influence of Intrinsic and Extrinsic Factors on Exposure of Prasugrel Active Metabolite in TRITON‐TIMI 38

E. Antman, E. Braunwald, S. Wiviott, 2009, Journal of clinical pharmacology.

Randomized Comparison of Prasugrel (CS-747, LY640315), a Novel Thienopyridine P2Y12 Antagonist, With Clopidogrel in Percutaneous Coronary Intervention: Results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)–TIMI 26 Trial

E. Antman, E. Braunwald, S. Murphy, 2005, Circulation.

Assessment of the clinical effects of cholesteryl ester transfer protein inhibition with evacetrapib in patients at high-risk for vascular outcomes: Rationale and design of the ACCELERATE trial.

D. Rader, P. Barter, A. Tall, 2015, American heart journal.

Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial

J. Rosenstock, R. Heine, S. Kahn, 2021, The Lancet.

Transfusion outcomes in patients undergoing coronary artery bypass grafting treated with prasugrel or clopidogrel: TRITON-TIMI 38 retrospective data analysis.

Peter K. Smith, R. Poston, L. Goodnough, 2013, The Journal of thoracic and cardiovascular surgery.

Relationship Between Exposure to Prasugrel Active Metabolite and Clinical Outcomes in the TRITON‐TIMI 38 Substudy

Junxiang Luo, C. Ernest, R. Wrishko, 2012, Journal of clinical pharmacology.

Abstract 4001: Relationship between Exposure to the Prasugrel Active Metabolite with TIMI Major/Minor Bleeding in TRITON-TIMI 38

E. Antman, S. Wiviott, C. Ernest, 2008 .

Greater Inhibition of Platelet Aggregation and Reduced Response Variability With Prasugrel Versus Clopidogrel: An Integrated Analysis

K. Winters, G. Weerakkody, J. Jakubowski, 2007, Journal of cardiovascular pharmacology and therapeutics.

Dose-Dependent Inhibition of Human Platelet Aggregation by Prasugrel and its Interaction With Aspirin in Healthy Subjects

K. Winters, G. Weerakkody, J. Jakubowski, 2007, Journal of cardiovascular pharmacology.

The Role of Lipoprotein (a) as a Marker of Residual Risk in Patients With Diabetes and Established Cardiovascular Disease on Optimal Medical Therapy: Post Hoc Analysis of ACCELERATE

A. Lincoff, S. Nissen, E. McErlean, 2019, Diabetes Care.

Transitioning to active-controlled trials to evaluate cardiovascular safety and efficacy of medications for type 2 diabetes

S. Nissen, D. McGuire, S. Nicholls, 2022, Cardiovascular Diabetology.

Designing, Conducting, Monitoring, and Analyzing Data from Pragmatic Randomized Clinical Trials: Proceedings from a Multi-stakeholder Think Tank Meeting

Lin Wang, Adrian F Hernandez, Jesse A Berlin, 2020, Therapeutic Innovation & Regulatory Science.

Stereoselective Metabolism of Prasugrel in Humans Using a Novel Chiral Liquid Chromatography-Tandem Mass Spectrometry Method

G. Weerakkody, N. Farid, A. Kurihara, 2007, Drug Metabolism and Disposition.

Running Head: COMPUTERS AND MATHEMATICS ACHIEVEMENT An Analysis of NAEP Trial State Assessment Data Concerning the Effects of Computers on Mathematics Achievement

Thomas A. DeVaney, G. Weerakkody, T. DeVaney, 2012 .

Abstract 10881: Mortality Benefit with Prasugrel in TRITON - TIMI 38 Coronary Artery Bypass Grafting (CABG) Cohort: Risk Adjusted Retrospective Data Analysis

Peter K. Smith, R. Poston, L. Goodnough, 2010 .

Variance component estimation in multiple regression models having a nested error structure

Dallas Johnson, G. Weerakkody, 1990 .

Randomized Comparison of Prasugrel (CS-747, LY640315), a Novel Thienopyridine P2Y 12 Antagonist, With Clopidogrel in Percutaneous Coronary Intervention Results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)–TIMI 26 Trial Coronary Heart Disease

E. Antman, S. Murphy, C. McCabe, 2005 .

Prasugrel versus clopidogrel in patients with acute coronary syndromes.

E. Antman, E. Braunwald, S. de Servi, 2007, The New England journal of medicine.

The Platelet Inhibitory Effects and Pharmacokinetics of Prasugrel After Administration of Loading and Maintenance Doses in Healthy Subjects

K. Winters, G. Weerakkody, J. Jakubowski, 2006, Journal of cardiovascular pharmacology.

Estimating Dose Equivalence for New Routes of Drug Administration

J. Chien, D. Muchmore, G. Weerakkody, 2004, Journal of biopharmaceutical statistics.

Impact of Baseline Glycemic Control on Residual Cardiovascular Risk in Patients With Diabetes Mellitus and High‐Risk Vascular Disease Treated With Statin Therapy

J. S. St. John, A. Lincoff, S. Nissen, 2019, Journal of the American Heart Association.

Predicting seed yield of moist-soil plants

G. Weerakkody, R. Kaminski, M. Gray, 1999 .

Evacetrapib and Cardiovascular Outcomes in High‐Risk Vascular Disease

C. Granger, D. Rader, P. Barter, 2017, The New England journal of medicine.

Effects of the Proton Pump Inhibitor Lansoprazole on the Pharmacokinetics and Pharmacodynamics of Prasugrel and Clopidogrel

K. Winters, G. Weerakkody, J. Brandt, 2008, Journal of clinical pharmacology.

TESTING HYPOTHESES ABOUT THE COMMON MEAN OF TWO NORMAL POPULATIONS

G. Weerakkody, 1992 .

Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38).

E. Antman, E. Braunwald, C. McCabe, 2006, American heart journal.

Plasma Aldosterone Levels Are Not Associated With Cardiovascular Events Among Patients With High‐Risk Vascular Disease: Insights From the ACCELERATE Trial

A. Lincoff, S. Nissen, E. McErlean, 2019, Journal of the American Heart Association.

Effect of CETP inhibition with evacetrapib in patients with diabetes mellitus enrolled in the ACCELERATE trial

J. S. St. John, A. Lincoff, S. Nissen, 2020, BMJ Open Diabetes Research & Care.

Comparison of speed of onset of platelet inhibition after loading doses of clopidogrel versus prasugrel in healthy volunteers and correlation with responder status.

K. Winters, M. Warner, G. Weerakkody, 2007, The American journal of cardiology.

A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation.

K. Winters, S. Wiviott, G. Weerakkody, 2007, American heart journal.

Reduction in recurrent cardiovascular events with prasugrel compared with clopidogrel in patients with acute coronary syndromes from the TRITON-TIMI 38 trial

E. Antman, E. Braunwald, S. Murphy, 2008, European heart journal.

Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis

N. Sattar, S. Zoungas, D. McGuire, 2022, Nature medicine.

Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis

N. Sattar, S. Zoungas, D. McGuire, 2022, Nature Medicine.

Baseline fasting plasma insulin levels predict risk for major adverse cardiovascular events among patients with diabetes and high-risk vascular disease: Insights from the ACCELERATE trial

S. Kashyap, A. Lincoff, S. Nissen, 2019, Diabetes & vascular disease research.

Diagnoses of gastrointestinal cancers after gastrointestinal bleeding in patients receiving clopidogrel or warfarin.

J. Wernicke, G. Weerakkody, A. Asiimwe, 2013, Current drug safety.

Validation of the Soil Temperature Subroutine HEAT in the Cotton Simulation Model GOSSYM

F. D. Whisler, Govinda Weerakkody, Mariquita Y. L. Boone, 1997 .

Abstract 17400: Lipoprotein(a) is a Determinant of Residual Cardiovascular Risk in the Setting of Optimal LDL-C in Statin-Treated Patients With Atherosclerotic Cardiovascular Disease

S. Nissen, E. McErlean, S. Nicholls, 2017 .

Limits of retrospective power analysis

Patrick D. Gerard, David R. Smith, P. Gerard, 1998 .

COMPARED TO INSULIN GLARGINE, TIRZEPATIDE REDUCES THE PREVALENCE OF THE METABOLIC SYNDROME IN PATIENTS WITH TYPE 2 DIABETES AND HIGH CARDIOVASCULAR RISK: POST-HOC ANALYSIS OF SURPASS-4

S. Nicholls, I. Pávó, G. Weerakkody, 2023, Journal of the American College of Cardiology.

Mortality benefit with prasugrel in the TRITON-TIMI 38 coronary artery bypass grafting cohort: risk-adjusted retrospective data analysis.

R. Poston, L. Goodnough, G. Weerakkody, 2012, Journal of the American College of Cardiology.

Mortality benefit with prasugrel in the TRITON-TIMI 38 coronary artery bypass grafting cohort: risk-adjusted retrospective data analysis.

G. Weerakkody, L. Lenarz, Lawrence T. Goodnough, 2012, Journal of the American College of Cardiology.

Improvements in post‐challenge lipid response following tirzepatide treatment in patients with type 2 diabetes

K. Mather, G. Weerakkody, A. Haupt, 2023, Diabetes, obesity & metabolism.

Estimating the correlation coefficient in the presence of correlated observations from a bivariate normal population

G. Weerakkody, S. Givaruangsawat, 1995 .

Mortality benefit with prasugrel in the TRITON-TIMI 38 coronary artery bypass grafting cohort: risk-adjusted retrospective data analysis.

G. Weerakkody, L. Lenarz, Lawrence T. Goodnough, 2012, Journal of the American College of Cardiology.

Achieving Normoglycemia With Tirzepatide: Analysis of SURPASS 1–4 Trials

S. Del Prato, G. Weerakkody, L. F. Landó, 2023, Diabetes care.

Comparison of Tirzepatide and Dulaglutide on Major Adverse Cardiovascular Events in Participants with Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: SURPASS-CVOT Design and Baseline Characteristics.

Deepak L. Bhatt, A. Lincoff, Darren K Mcguire, 2023, American heart journal.